Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043287 · ClinicalTrials.gov registry record
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 420
- Enrollment target
NCT03043287 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 420 participants.
The verdict
NCT03043287 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 420 participants
- Enrollment target
Study Summary
This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.
Interventions
- BIOLOGICAL onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2017-05-12 |
| Est. Completion | 2019-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043287
The ClinicalTrials.gov registry entry for NCT03043287 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT03043287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03043287 about?
NCT03043287 is a clinical study titled "Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)". This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.
What is the current status of trial NCT03043287?
This trial is currently completed. The enrollment target is 420 participants. The study started on 2017-05-12. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03043287?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03043287?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.